Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patients with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein

Hepatology Research

Volumn 37, Issue 11, 2007, Pages 914-922

  Kobayashi, Makoto ^a   Kuroiwa, Takashi ^a   Suda, Takeshi ^a   Tamura, Yasushi ^a   Kawai, Hirokazu ^a   Igarashi, Masato ^a   Fukuhara, Yasuo ^a   Aoyagi, Yutaka ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Alpha fetoprotein; Hepatocellular carcinoma; L3; Prognostic factor; Survival rate

Indexed keywords

ALPHA FETOPROTEIN; PROTEIN L3; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOELECTROPHORESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

EID: 34548628973     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00147.x     Document Type: Article

References (28)

1. Okuda K. Hepatocellular carcinoma. J Hepatology 2000; 32 (Suppl 1): 225-37.
2. Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res 1968; 28: 1344-50.
3. O'Conor GI, Tatarinov YS, Abelev GI, Uriel J. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer 1970; 25: 1091-8.
4. Aoyagi Y, Suzuki Y, Isemura M et al. Differential reactivity of alpha-fetoprotein with lectins and evaluation of its usefulness in the diagnosis of hepatocellular carcinoma. Gann 1984; 75: 809-15.
5. Aoyagi Y, Isemura M, Suzuki Y et al. Fucosylated alpha-fetoprotein as marker of early hepatocellular carcinoma. Lancet 1985; ii: 1353-4.
6. Aoyagi Y, Suzuki Y, Isemura M et al. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer 1988; 61: 769-74.
7. Breborowicz J, Mackiewicz A, Breborowicz D. Microheterogeneity of alpha-fetoprotein in patient serum as demonstrated by lectin affinoelectrophoresis. Scand J Immunol 1981; 14: 15-20.
8. Taketa K, Sekiya C, Namiki M et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 1990; 99: 508-18.
9. Taketa K, Endo Y, Sekiya C et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993; 53: 5419-23.
10. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T. A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995; 22: 802-7.
11. Aoyagi Y, Isemura M, Yosizawa Z et al. Fucosylation of serum alpha-fetoprotein with primary hepatocellular carcinoma. Biochim Biophys Acta 1985; 830: 217-23.
12. Aoyagi Y, Suzuki Y, Igarashi K et al. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: Presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer 1993; 67: 486-92.
13. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996; 111: 996-1001.
14. Aoyagi Y, Isokawa O, Suda T, Watanabe M, Suzuki Y, Asakura H. Fucosylation index of alpha-fetoprotein as a possible prognostic indicator in patients with hepatocellular carcinoma. Cancer 1998; 83: 2076-82.
15. Katoh H, Nakamura K, Tanaka T, Satomura S, Matsuura S. Automatic and simultaneous analysis of Lens culinaris agglutinin-reactive alpha-fetoprotein ratio and total alpha-fetoprotein concentration. Anal Chem 1998; 70: 2110-14.
16. Matsui O, Kadoya M, Kameyama T et al. Benign and malignant nodules in cirrhotic livers: Distinction based on blood supply. Radiology 1991; 178: 493-7.
17. Kadoya M, Matsui O, Takashima T, Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 1992; 183: 819-25.
18. Taketa K, Ichikawa E, Taga H, Hirai H. Antibody-affinity blotting, a sensitive technique for the detection of alpha-fetoprotein separated by lectin affinity electrophoresis in agarose gels. Electrophoresis 1985; 6: 492-7.
19. Sobin LH, Witterkind C. TNM Classification of Malignant Tumors, (UICC), 5th edn. New York: John Wiley and Sons, 1997.
20. Karvountzis GG, Redeker AG. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis. Intern Med 1974; 80: 156-60.
21. Chen D-S, Sung J-L. Serum alpha-fetoprotein in hepatocellular carcinoma. Cancer 1977; 40: 779-83.
22. Alpert E, Feller ER. Alpha-fetoprotein (AFP) in benign liver diseases. Evidence that normal liver regeneration does not induce AFP synthesis. Gastroenterology 1978; 74: 856-8.
23. Uozumi N, Yanagidani S, Miyoshi E et al. Purification and cDNA cloning of porcine brain GDP-L-Fuc: N-Acetyl-β-D-glucosaminide α1→6fucosyltransferase. J Biol Chem 1996; 271: 27810-17.
24. Yanagidani S, Uozumi N, Ihara Y, Miyoshi E, Yamaguchi N, Taniguchi N. Purification and cDNA cloning of GDP-L-Fuc: N-acetyl-beta-D-glucosaminide: Alpha1-6 fucosyltransferase (alpha1-6 FucT) from human gastric cancer MKN45 cells. J Biochem 1997; 121: 626-32.
25. Uozumi N, Teshima T, Yamamoto T et al. A fluorescent assay method for GDP-L-Fuc: N-Acetyl-β-D-glucosaminide α1-6fucosyltransferase activity, involving high performance liquid chromatography. J Biochem 1996; 120: 385-92.
26. Mita Y, Aoyagi Y, Suda T, Asakura H. Plasma fucosyltransferase activity in patients with hepatocellular carcinoma, with special reference to correlation with fucosylated species of alpha-fetoprotein. J Hepatology 2000; 32: 946-54.
27. Tada T, Kumada T, Toyoda H et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25: 848-53.
28. Okuda H, Saito A, Shiratori K, Yamamoto M, Takasaki K, Nakano M. Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3. J Gastroenterol Hepatol 2005; 20: 759-64.